interesting that people are focused on SK shortcom

interesting that people are focused on SK shortcomings here - puzzling really. To each his own - I think he's impressive and very credible. And we don't have another viabile spokesman right now. Clearly finding someone really good who is willing to jump on board as CEO (given the FDA headline BS over the past year) isn't easy or something would've happened over past 2 months. I agree he's not perfect, but i would lean toward keeping the only impressive guy we have to speak to potential partners.

The good news is that the people making these decisions (Urbach, etc.) realize this is the case - which is why SK is still here and not going anywhere.